

*A  
cont.*

2. The method of claim 1 wherein said at least one antihyperglycemic agent is a biguanide.
3. The method of claim 2 wherein said biguanide is metformin or a pharmaceutically acceptable salt thereof.

---

*AK  
Sul  
p*

22. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean  $AUC_{0-\infty}$  of  $18277 \pm 2961$  ng·hr/ml and a mean  $C_{max}$  of  $1929 \pm 333$  ng/ml, based on administration of a 1700 mg once-a-day dose of metformin after an evening meal.
23. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean  $AUC_{0-\infty}$  of  $20335 \pm 4360$  ng·hr/ml and a mean  $C_{max}$  of from  $2053 \pm 447$  ng/ml, based on administration of a 2000 mg once-a-day dose of metformin after an evening meal.
24. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean  $AUC_{0-24}$  of  $26818 \pm 7052$  ng·hr/ml and a mean  $C_{max}$  of  $2849 \pm 797$  ng/ml, based on administration of a 2000 mg once-a-day dose of metformin after an evening meal.
25. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean  $AUC_{0-24}$  of  $22590 \pm 3626$  ng·hr/ml and a mean  $C_{max}$  of  $2435 \pm 630$  ng/ml on the first day of administration and a mean  $AUC_{0-24}$  of  $24136 \pm 7996$  ng·hr/ml and a mean  $C_{max}$  of  $2288 \pm 736$  ng/ml on the 14<sup>th</sup> day of administration, based on administration of a 2000 mg once-a-day dose of metformin after an evening meal.
26. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean  $T_{1/2}$  from 2.8 to 4.4.

---